Alphatec Holdings (ATEC) reported $764M in revenue for fiscal 2025, +25.0% year on year. That ranks #1945 by revenue among 2853 SEC filers and #183 in Healthcare. It posted a net loss of −$143M for the same year. Revenue has grown 10.1% a year on average since 2011 ($198M then). The fiscal 2025 balance sheet shows $791M in total assets, $161M in cash and $501M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerIncludingAssessedTax | $764M | +25.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $532M | +25.4% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$82.1M | +$54.0M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$143M | +$18.8M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $45.2M | +$89.9M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $42.5M | −49.0% | FY20252025-12-31 |
| Total assetsAssets | $791M | +2.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $12.4M | +$26.6M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $161M | +15.8% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $501M | −12.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $192M | −$33.9M | Open → |
| Q2 20262026-06-30 | $214M | −$25.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Alphatec Holdings, Inc.
- Ticker
- ATEC
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001350653
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Telix PharmaceuticalsTLX | $804M | −$7.1M |
| U S Physical TherapyUSPH | $781M | $39.6M |
| Collegium PharmaceuticalCOLL | $781M | $63.0M |
| Alphatec HoldingsATEC | $764M | −$143M |
| Corcept TherapeuticsCORT | $761M | $99.7M |
| Irhythm HoldingsIRTC | $747M | −$45.0M |
| Emergent BiosolutionsEBS | $743M | $52.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Alphatec Holdings — Key figures |url=https://companiesranked.com/en/company/alphatec-holdings |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Alphatec Holdings — Key figures. CompaniesRanked. https://companiesranked.com/en/company/alphatec-holdingsBibTeX
@misc{companiesranked-en-company-alphatec-holdings-2026,
author = {{CompaniesRanked}},
title = {{Alphatec Holdings — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/alphatec-holdings}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-067393 · February 24, 2026
{{cite web |title=Alphatec Holdings — Key figures — 10-K (0001193125-26-067393) |url=https://www.sec.gov/Archives/edgar/data/1350653/000119312526067393/atec-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.